Investors Encouraged to Join the Class Action Lawsuit Against Applied Therapeutics
Rosen Law Firm, recognized for its commitment to investor rights, is reminding those who purchased securities of Applied Therapeutics, Inc. (NASDAQ: APLT) from January 3, 2024, to December 2, 2024, about an important opportunity to seek compensation through a class action lawsuit.
Class Action Overview
If you acquired Applied Therapeutics securities within this specified period, you may be entitled to compensation with no upfront costs or fees due to a contingency arrangement. The deadline to take action is pressing, as potential lead plaintiffs must move by February 18, 2025. This is a critical date for anyone wishing to represent fellow investors.
What Happens Next?
To explore your options in joining this class action, please reach out to the Rosen Law Firm. They recommend getting in touch with Phillip Kim, Esq., by calling toll-free at 866-767-3653 for detailed information on how to proceed.
The Role of the Lead Plaintiff
The lead plaintiff plays a crucial role in guiding the class action lawsuit on behalf of all class members. If you are interested in taking on this responsibility, it is imperative to act quickly to ensure your representation in court.
Why Choose Rosen Law Firm?
Rosen Law Firm has a proven track record in conducting rigorous litigation for its clients. Investors are advised to select legal counsel wisely, ensuring they collaborate with a firm that possesses substantial experience in securities class actions. Notably, Rosen Law Firm has achieved significant settlements, including the largest ever against a Chinese company at one point.
A Track Record of Success
The firm has consistently ranked among the top law firms for class action settlements, recovering hundreds of millions for investors over the years. In 2019 alone, they facilitated over $438 million in recoveries. Laurence Rosen, a co-founding partner, has even been recognized for his noteworthy contributions to the plaintiffs' bar.
Details of the Allegations
The lawsuit alleges that statements made by Applied Therapeutics during the class period were misleading. Specifically, they purportedly concealed crucial details regarding clinical trial protocols, leading investors to believe that all regulatory practices were being adhered to. When the actual circumstances were disclosed, a significant risk materialized concerning the FDA's approval of the New Drug Application, reportedly causing substantial investor losses.
Investors' Rights and Next Steps
Every investor holds the right to join the class action and share in any potential recoveries, though no class has yet been certified. Clients can either take an active role by selecting their counsel or opt to remain passive class members until further developments occur. Joining the class action does not mandate participation as lead plaintiff.
Stay Updated with Investor News
For those interested in ongoing updates and news regarding this case, it's recommended to follow Rosen Law Firm on social platforms such as LinkedIn, Twitter, and Facebook.
Frequently Asked Questions
Who qualifies to join the APLT class action lawsuit?
Anyone who purchased securities of Applied Therapeutics from January 3, 2024, to December 2, 2024, is eligible.
What is the deadline to participate in this class action?
The deadline to move as lead plaintiff is February 18, 2025.
What is the role of a lead plaintiff in a class action lawsuit?
The lead plaintiff acts on behalf of all other class members, directing the litigation process.
What does it cost to join the class action?
Joining the class action is generally at no cost due to a contingency fee arrangement.
Can I join the lawsuit if I'm not the lead plaintiff?
Yes, you can still participate in the class action without serving as the lead plaintiff.
